Sanofi plans to boost stake in Regeneron

Hannah Blake


Sanofi has announced its plans to buy more shares in US biotech, Regeneron Pharmaceuticals. The French drugmaker currently controls approximately 17% of Regeneron.

Due to a long-term partnership co-developing potential blockbuster drugs for high cholesterol levels and rheumatoid arthritis, Sanofi has a right to raise its stake in Regeneron to as much as 30%. But a 2007 agreement means Sanofi can’t purchase more than this amount.

Under terms of the partnership, Sanofi and Regeneron agreed to split any US profits from the medicines co-developed equally. Last year, the US FDA approved Zaltrap, co-developed by this partnership, for metastatic colorectal cancer.

However, analysts are saying that this does not necessarily mean that an acquisition is on the cards.


Related news:

Sanofi boosting stake in Regeneron (Reuters)

Regeneron Says Sanofi Plans to Lift Stake (Wall Street Journal)

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.